Thomas Herzog MD
Gynecologic Oncology
Professor of Obstetrics & Gynecology, Columbia P&S
Join to view full profile
2139 Auburn AveCincinnati, OH 45219
Phone+1 513-585-2323
Fax+1 513-585-4893
Dr. Herzog is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Gynecologic Oncology, 1990 - 1993
TriHealth (Bethesda North and Good Samaritan Hospitals)Residency, Obstetrics and Gynecology, 1986 - 1990
University of Cincinnati College of MedicineClass of 1986
Certifications & Licensure
OH State Medical License 1988 - 2026
NY State Medical License 2004 - 2015
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Publications & Presentations
PubMed
- Corrigendum to "Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industr...Robert L Coleman, Isabelle Ray-Coquard, Thomas J Herzog, Antonio González-Martín, Brian Slomovitz
International Journal of Gynecological Cancer. 2026-08-01 - Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.Evelyn Cantillo, Vivek Podder, Natalie Danziger, Dale Lobo, Douglas I Lin
JCO Precision Oncology. 2026-07-01 - Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc's Scholar Career Development Award and New In...Angeles Alvarez Secord, Ronald D Alvarez, Leslie M Randall, Robert S Mannel, David G Mutch
International Journal of Gynecological Cancer. 2026-05-01
Other
- Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancerHerzog TJ
http://www.uptodate.com/contents/adjuvant-therapy-of-early-stage-stage-i-and-ii-epithelial-ovarian-f
UpToDate, Wolters Kluwer Health - 2012-11-13 - First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancerHerzog TJ
http://www.uptodate.com/contents/first-line-chemotherapy-for-advanced-stage-iii-or-iv-epithelial-ova
UpToDate, Wolters Kluwer Health - 2013-04-08
Press Mentions
Platform-Predicted Treatments Improve Outcomes for Platinum-Resistant Ovarian CancerApril 7th, 2025- Platform-Predicted Treatments Improve Outcomes for Platinum-Resistant Ovarian CancerApril 5th, 2025
- Study: Platform-Predicted Treatments Improve Outcomes for Platinum-Resistant Ovarian CancerApril 4th, 2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
